Paper · 42434841
Carrier-Free Nanoparticles Enhance Photothermal-Immune Therapy via Metabolic Reprogramming in Triple-Negative Breast Cancer.
Hou Y and 13 others. Adv Healthc Mater, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Carrier-Free Nanoparticles Enhance Photothermal-Immune Therapy via Metabolic Reprogramming in Triple-Negative Breast Cancer. Papers, record 42434841. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42434841
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Carrier-Free Nanoparticles Enhance Photothermal-Immune Therapy via Metabolic Reprogramming in Triple-Negative Breast Cancer.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Triple Negative Breast Neoplasms | Major topic |
| Nanoparticles | Major topic |
| Photothermal Therapy | Major topic |
| Immunotherapy | Major topic |
| Animals | |
| Humans | |
| Female | |
| Metabolic Reprogramming | |
| Cell Line, Tumor | |
| Mice | |
| Mice, Nude | |
| Tumor Microenvironment | |
| Indoles | |
| Methionine | |
| Mice, Inbred BALB C |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| LQN25H300008 | Natural Science Foundation of Zhejiang Province | PubMed | ||
| 2025ZJLP05 | Clinical Drug Evaluation and Research Special Scientific Funding Project of the Zhejiang Province Pharmaceutical Association | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References53
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39,801,503 | Finely Tailored Conjugated Small Molecular Nanoparticles for Near-Infrared Biomedical Applications. | Research (Wash D C) | 2025 | https://conductscience.org/library/papers/39801503 | PubMed |
| 2 | 40,584,786 | Tumor Microenvironment-Responsive Nanoparticles: Promising Cancer PTT Carriers. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/40584786 | PubMed |
| 3 | 39,163,559 | Carrier-Free Nanodrugs: From Bench to Bedside. | ACS Nano | 2024 | https://conductscience.org/library/papers/39163559 | PubMed |
| 4 | 34,820,552 | Resetting amino acid metabolism of cancer cells by ATB0,+-targeted nanoparticles for enhanced anticancer therapy. | Bioact Mater | 2022 | https://conductscience.org/library/papers/34820552 | PubMed |
| 5 | 38,889,339 | Co-delivery Nano System of MS-275 and V-9302 Induces Pyroptosis and Enhances Anti-Tumor Immunity Against Uveal Melanoma. | Adv Sci (Weinh) | 2024 | https://conductscience.org/library/papers/38889339 | PubMed |
| 6 | 41,235,469 | Pyroptosis-Inducing Nanoplatform with Plasmonic-Enhanced Phototherapy for Metastasis-Suppressive Cancer Immunotherapy. | ACS Nano | 2025 | https://conductscience.org/library/papers/41235469 | PubMed |
| 7 | 37,797,194 | Gold Nanoparticles Capped with a Novel Titanium(IV)-Containing Polyoxomolybdate Cluster: Selective and Enhanced Bactericidal Effect Against Escherichia coli. | Small | 2024 | https://conductscience.org/library/papers/37797194 | PubMed |
| 8 | 37,820,582 | The cancer-immunity cycle: Indication, genotype, and immunotype. | Immunity | 2023 | https://conductscience.org/library/papers/37820582 | PubMed |
| 9 | 41,267,037 | ZNF526 drives tumor growth by enhancing SHMT1-dependent serine metabolism and antioxidant capability in TNBC. | Mol Cancer | 2025 | https://conductscience.org/library/papers/41267037 | PubMed |
| 10 | 32,373,196 | The role of transporters in cancer redox homeostasis and cross-talk with nanomedicines. | Asian J Pharm Sci | 2020 | https://conductscience.org/library/papers/32373196 | PubMed |
1 to 10 of 53
See all 53 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
None in this release.
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MAT2A | 4,144 | PubTator's text mining | https://conductscience.org/library/genes/4144 |
Source NCBI Gene
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42434841
GET https://conductscience.org/api/papers/v1/42434841/references?page=2